[go: up one dir, main page]

BR0211565A - Derivados de diamina - Google Patents

Derivados de diamina

Info

Publication number
BR0211565A
BR0211565A BR0211565-4A BR0211565A BR0211565A BR 0211565 A BR0211565 A BR 0211565A BR 0211565 A BR0211565 A BR 0211565A BR 0211565 A BR0211565 A BR 0211565A
Authority
BR
Brazil
Prior art keywords
alkyl
optionally substituted
dialkyl
alkoxy
alkylene
Prior art date
Application number
BR0211565-4A
Other languages
English (en)
Inventor
Toshiharu Ohta
Satoshi Komoriya
Toshiharu Yoshino
Kouichi Uoto
Yumi Nakamoto
Hiroyuki Naito
Akiyoshi Mochizuki
Tsutomu Nagata
Hideyuki Kanno
Noriyasu Haginoya
Kenji Yoshikawa
Masatoshi Nagamochi
Syozo Kobayashi
Makoto Ono
Original Assignee
Daiichi Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/JP2002/002683 external-priority patent/WO2003000657A1/ja
Priority claimed from PCT/JP2002/006141 external-priority patent/WO2003000680A1/ja
Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co
Publication of BR0211565A publication Critical patent/BR0211565A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0827Tripeptides containing heteroatoms different from O, S, or N

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

"DERIVADOS DE DIAMINA". Descreve-se compostos representados pela fórmula genérica (1), seus sais, seus solvatos, ou seus N-óxidos: Q^ 1^ -Q^ 2^ -T^ 0^ -N (R^ 1^) -Q^ 3^-N (R^ 2^)-T^ 1^ -Q^ 4^ (1) onde R^ 1^ e R^ 2^ representam, cada um, hidrogênio, etc. Q^ 1^ representa hidrocarbila com 5 ou 6 membros, saturada ou insaturada, opcionalmente substituída, etc.; Q^ 2^ representa uma ligação simples, etc.; Q^ 3^ representa o seguinte grupo: onde é Q^ 5^ representa alquileno de C~ 1-8~, etc. ; e T^ 0^ e T^ 1^ representam, cada um, carbonila, etc. Estes compostos são úteis como preventivos e/ou medicamentos para infarto cerebral, embolia cerebral, infarto do miocárdio, angina, infarto pulmonar, embolia pulmonar, doença de Buerger, trombose venosa profunda, coagulação intravascular disseminada, trombose após substituição por válvula ou articulação artificial, trombose e reoclusão após reconstrução circulatória, síndrome da resposta inflamatória sistêmica (SIRS), disfunção de múltiplos órgãos (MODS), trombose em circulação extracorpórea, ou coagulação sang³ínea após coleta de sangue.
BR0211565-4A 2001-08-09 2002-08-08 Derivados de diamina BR0211565A (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP2001243046 2001-08-09
JP2001311808 2001-10-09
JP2001398708 2001-12-28
PCT/JP2002/002683 WO2003000657A1 (en) 2001-06-20 2002-03-20 Diamine derivatives
PCT/JP2002/006141 WO2003000680A1 (en) 2001-06-20 2002-06-20 Diamine derivatives
PCT/JP2002/008119 WO2003016302A1 (en) 2001-08-09 2002-08-08 Diamine derivatives

Publications (1)

Publication Number Publication Date
BR0211565A true BR0211565A (pt) 2004-06-29

Family

ID=32600712

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0211565-4A BR0211565A (pt) 2001-08-09 2002-08-08 Derivados de diamina

Country Status (15)

Country Link
EP (1) EP1415992B1 (pt)
JP (1) JP4331595B2 (pt)
KR (1) KR100908966B1 (pt)
CN (1) CN100545160C (pt)
AT (1) ATE556066T1 (pt)
AU (1) AU2002328596B2 (pt)
BR (1) BR0211565A (pt)
CA (1) CA2456841A1 (pt)
ES (1) ES2383749T3 (pt)
IL (2) IL160204A0 (pt)
MX (1) MXPA04001272A (pt)
NO (1) NO327003B1 (pt)
PL (1) PL368402A1 (pt)
RU (1) RU2314303C2 (pt)
WO (1) WO2003016302A1 (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI290136B (en) 2000-04-05 2007-11-21 Daiichi Seiyaku Co Ethylenediamine derivatives
US7365205B2 (en) 2001-06-20 2008-04-29 Daiichi Sankyo Company, Limited Diamine derivatives
IL159438A0 (en) * 2001-06-20 2004-06-01 Daiichi Seiyaku Co Diamine derivatives
RU2333203C2 (ru) * 2002-12-25 2008-09-10 Дайити Фармасьютикал Ко., Лтд. Диаминовые производные
US7291615B2 (en) 2003-05-01 2007-11-06 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
US7378409B2 (en) 2003-08-21 2008-05-27 Bristol-Myers Squibb Company Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity
HUE039135T2 (hu) 2003-11-12 2018-12-28 Daiichi Sankyo Co Ltd Eljárás tiazolszármazék elõállítására
AU2004312530A1 (en) 2003-12-29 2005-07-21 Sepracor Inc. Pyrrole and pyrazole DAAO inhibitors
CN103214414B (zh) * 2005-09-16 2016-02-17 第一三共株式会社 旋光性的二胺衍生物及其制造方法
ES2566479T3 (es) 2006-01-06 2016-04-13 Sunovion Pharmaceuticals Inc. Inhibidores de reabsorción de monoamina con base en tetralona
KR101294014B1 (ko) 2006-01-06 2013-08-09 선오비온 파마슈티컬스 인코포레이티드 모노아민 재흡수 저해제로서의 시클로알킬아민
EP2816024B8 (en) 2006-03-31 2018-04-04 Sunovion Pharmaceuticals Inc. Chiral amines
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
WO2008026563A1 (en) 2006-08-30 2008-03-06 Shionogi & Co., Ltd. Hydrazine amide derivative
US7902252B2 (en) 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
MX351987B (es) 2007-03-29 2017-11-03 Daiichi Sankyo Co Ltd Composicion farmaceutica.
CN101686672A (zh) 2007-05-31 2010-03-31 塞普拉柯公司 苯基取代的环烷胺作为一元胺再摄取抑制剂
CN102317248A (zh) * 2008-12-12 2012-01-11 第一三共株式会社 光学活性羧酸的生产方法
MY150973A (en) * 2008-12-17 2014-03-31 Daiichi Sankyo Co Ltd Method for producing diamine derivative
WO2010082531A1 (ja) 2009-01-13 2010-07-22 第一三共株式会社 活性化血液凝固因子阻害剤
CN102348688B (zh) 2009-03-10 2014-07-09 第一三共株式会社 用于制备二胺衍生物的方法
EP2407450B1 (en) 2009-03-13 2015-04-22 Daiichi Sankyo Company, Limited Method for producing optically active diamine derivative
WO2010131663A1 (ja) * 2009-05-15 2010-11-18 第一三共株式会社 オキサミド誘導体
ES2605034T3 (es) 2009-06-18 2017-03-10 Daiichi Sankyo Company, Limited Composición farmacéutica con solubilidad mejorada
WO2011059080A1 (ja) * 2009-11-16 2011-05-19 第一三共株式会社 同位体置換されたジアミン誘導体
WO2011102505A1 (ja) 2010-02-22 2011-08-25 第一三共株式会社 経口用徐放性固形製剤
WO2011102506A1 (ja) 2010-02-22 2011-08-25 第一三共株式会社 経口用徐放性固形製剤
JP5749247B2 (ja) 2010-02-22 2015-07-15 第一三共株式会社 経口用徐放性固形製剤
HUE031059T2 (en) 2010-03-19 2017-06-28 Daiichi Sankyo Co Ltd Procedure for improving anticoagulant administration
CA2793413C (en) 2010-03-19 2015-11-24 Daiichi Sankyo Company, Limited Crystal form of edoxaban tosylate monohydrate and method of producing same
WO2011149110A1 (en) 2010-05-28 2011-12-01 Daiichi Sankyo Company, Limited Novel composition for the prevention and/or treatment of thromboembolism
JP5780657B2 (ja) 2010-07-02 2015-09-16 第一三共株式会社 光学活性ジアミン誘導体の塩の製造方法
CA2807459C (en) 2010-08-04 2015-09-08 Daiichi Sankyo Company, Limited Process for preparing a compound by a novel sandmeyer-like reaction using a nitroxide radical compound as a reaction catalyst
ES2673182T3 (es) 2011-08-10 2018-06-20 Daiichi Sankyo Company, Limited Composición farmacéutica que contiene un derivado de diamina
RU2665372C2 (ru) 2012-09-03 2018-08-29 Дайити Санкио Компани, Лимитед Пероральная фармацевтическая композиция замедленного высвобождения, содержащая гидрохлорид гидроморфона
TWI602803B (zh) 2013-03-29 2017-10-21 第一三共股份有限公司 光學活性二胺衍生物之製造方法
WO2014157612A1 (ja) 2013-03-29 2014-10-02 第一三共株式会社 (1s,4s,5s)-4-ブロモ-6-オキサビシクロ[3.2.1]オクタン-7-オンの製造方法
HUE052100T2 (hu) 2014-02-18 2021-04-28 Daiichi Sankyo Co Ltd Eljárás aktivált véralvadási faktor X (FXA) inhibitorának alõállítására
JP2017210468A (ja) * 2016-05-23 2017-11-30 宇部興産株式会社 ヨードラクトン化合物の製造方法
JP6696474B2 (ja) * 2016-06-24 2020-05-20 宇部興産株式会社 オキサビシクロオクタン化合物の製造方法
CN106467475A (zh) * 2016-08-29 2017-03-01 上海大学 邻位双叠氮化合物的制备方法
CN107573256B (zh) * 2017-09-26 2020-02-21 安徽国星生物化学有限公司 一种对氯苯肼盐酸盐连续化生产方法及其装置
CN111138357B (zh) * 2018-11-06 2022-11-04 天津药物研究院有限公司 2-氧代-1,2-二氢喹啉类衍生物、其制备方法及其在医药上的应用
CN111606827B (zh) * 2020-06-23 2022-10-25 内蒙古京东药业有限公司 一种制备依度沙班手性胺中间体的方法
CN111763222B (zh) * 2020-08-03 2021-05-25 珠海市海瑞德新材料科技有限公司 用于制备依度沙班游离碱的中间体及其制备方法和应用
WO2022129535A1 (en) 2020-12-18 2022-06-23 Krka, D.D., Novo Mesto Edoxaban formulation containing no sugar alcohols

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986007257A2 (en) * 1985-06-07 1986-12-18 The Upjohn Company Antiarrhythmic use for aminocycloalkylamides
WO1992004017A1 (en) * 1990-09-10 1992-03-19 The Upjohn Company Cis-n-(2-aminocyclohexyl)benzamide and their enantiomers as anticonvulsants
ZA928276B (en) * 1991-10-31 1993-05-06 Daiichi Seiyaku Co Aromatic amidine derivates and salts thereof.
US5430150A (en) * 1992-12-16 1995-07-04 American Cyanamid Company Retroviral protease inhibitors
JPH09503994A (ja) * 1993-03-03 1997-04-22 イーライ・リリー・アンド・カンパニー バラノイド
DE19536783A1 (de) * 1995-09-21 1997-03-27 Diagnostikforschung Inst Bifunktionelle Nicotinamid-Chelatbildner vom Typ N¶2¶S¶2¶ für radioaktive Isotope
US6274715B1 (en) 1995-11-08 2001-08-14 Abbott Laboratories Tricyclic erythromycin derivatives
IT1291823B1 (it) * 1997-04-08 1999-01-21 Menarini Ricerche Spa Composti pseudo-peptidici, loro preparazione ed uso in formulazioni farmaceutiche
US6207679B1 (en) * 1997-06-19 2001-03-27 Sepracor, Inc. Antimicrobial agents uses and compositions related thereto
US6130349A (en) 1997-12-19 2000-10-10 The Board Of Trustees Of The Leland Stanford Junior University Catalytic compositions and methods for asymmetric allylic alkylation
GB9807104D0 (en) * 1998-04-02 1998-06-03 Chirotech Technology Ltd The preparation of phosphine ligands
DE19814801A1 (de) * 1998-04-02 1999-10-07 Basf Ag Verfahren zur Herstellung von 1,3,4-trisubstituierten 1,2,4-Triazoliumsalzen
JP4665239B2 (ja) * 1998-04-21 2011-04-06 アゲンニクス アーゲー 抗癌剤および抗増殖性薬剤としての5−アミノインデノ[1,2−c]ピラゾール−4−オン
CA2329770A1 (en) * 1998-06-30 2000-01-06 Ian Campbell Lennon The preparation of arylphosphines
TW434207B (en) * 1998-07-24 2001-05-16 Everlight Chem Ind Corp Chiral ligand and method for preparing cyanohydrins from aldehydes
US6747023B1 (en) * 1998-08-11 2004-06-08 Daiichi Pharmaceutical Co., Ltd. Sulfonyl derivatives
AU2241400A (en) * 1999-04-06 2000-10-12 Yamanouchi Pharmaceutical Co., Ltd. Novel thiazolobenzoimidazole derivative
GB9909592D0 (en) * 1999-04-26 1999-06-23 Chirotech Technology Ltd Process for the preparation of calanolide precursors
EP1185488A1 (fr) * 1999-06-15 2002-03-13 Rhodia Chimie Sulfonylamides et carboxamides et leur application en catalyse asymetrique
US6492408B1 (en) * 1999-07-21 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
TWI290136B (en) * 2000-04-05 2007-11-21 Daiichi Seiyaku Co Ethylenediamine derivatives
US7365205B2 (en) * 2001-06-20 2008-04-29 Daiichi Sankyo Company, Limited Diamine derivatives
IL159438A0 (en) * 2001-06-20 2004-06-01 Daiichi Seiyaku Co Diamine derivatives
ES2329881T3 (es) * 2001-09-21 2009-12-02 Bristol-Myers Squibb Company Compuestos que contienen lactama y derivados de los mismos como inhibidores del factor xa.
AU2002350217A1 (en) * 2001-12-04 2003-06-17 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
AU2003273179A1 (en) * 2002-05-10 2003-12-12 Bristol-Myers Squibb Company 1,1-disubstituted cycloalkyl derivatives as factor xa inhibitors

Also Published As

Publication number Publication date
EP1415992A1 (en) 2004-05-06
WO2003016302A1 (en) 2003-02-27
CN1894238A (zh) 2007-01-10
JPWO2003016302A1 (ja) 2004-12-02
KR20040023720A (ko) 2004-03-18
ES2383749T3 (es) 2012-06-26
IL160204A0 (en) 2004-07-25
RU2004106625A (ru) 2005-06-27
EP1415992A4 (en) 2006-07-26
CN100545160C (zh) 2009-09-30
ATE556066T1 (de) 2012-05-15
MXPA04001272A (es) 2004-05-27
KR100908966B1 (ko) 2009-07-22
RU2314303C2 (ru) 2008-01-10
NO20040557L (no) 2004-04-02
CA2456841A1 (en) 2003-02-27
IL160204A (en) 2010-11-30
NO327003B1 (no) 2009-04-06
HK1095814A1 (zh) 2007-05-18
JP4331595B2 (ja) 2009-09-16
EP1415992B1 (en) 2012-05-02
PL368402A1 (en) 2005-03-21
AU2002328596B2 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
BR0211565A (pt) Derivados de diamina
JP7269731B2 (ja) 標的タンパク質の分解向上のための化合物および方法
TR200003355T2 (tr) Sitokinin sebep olduğu hastalıkların tedavisinde benzamid türevlerinin kullanılması
NZ509318A (en) Amide derivatives, their preparation and use in the treatment of diseases mediated by cytokines
WO2006138265A3 (en) Heterocyclic aspartyl protease inhibitors, preparation and use thereof
SG146694A1 (en) 1,1,1-trifluoro-4-phenyl-4-methyl-2-(1h-pyrrolo-2,3-c pyridin-2- ylmethyl)pentan-2-ol derivatives and related compounds as glucocorticoid ligands for the treatment of inflammatory diseases and diabetes
TW200500362A (en) 5-membered heteroaromatic ring compound and pharmaceutical use thereof
ATE286026T1 (de) Amid-derivate und deren medizinische verwendung
GEP20084447B (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
WO2006078283A3 (en) Quinoxaline inhibitors of hedgehog signalling
DE69528485D1 (de) Biphenylderivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
CA2405521A1 (en) Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties
EP1548008A4 (en) COMPOUND WITH TGF-BETA-HEMMENDER EFFECT AND THIS MEDICAL COMPOSITION CONTAINING
DE69530683D1 (de) Sulfonamid derivate und deren verwendung
WO2002085909A8 (en) 9-deazaguanine derivatives as inhibitors of gsk-3
HRP20130664T1 (en) Heterocyclic aspartyl protease inhibitors
DE59608740D1 (de) Cyclische und heterocyclische n-substituierte alpha-iminohydroxam- und carbonsäuren
WO2002044157A3 (en) Parb inhibitors
DE60012502D1 (de) Neue cathechole als antimikrobielle mittel
DE69316067D1 (de) Arzneimittel zur Verwendung bei der Behandlung von Parkinsonismus
DK0669912T3 (da) N-(3-Piperidinylcarbonyl)-beta-alaninderivater som PAF-antagonister
JP2003183286A5 (pt)
ATE388939T1 (de) N-((piperazinyl)hetaryl)arylsulfonamid-derivate mit affinität zum dopamin-d3-rezeptor
WO2004047738A3 (en) Arylcyclopropylcarboxylic amides as potassium channel openers
BRPI0407578A (pt) derivados da purina, processo de preparação, sua aplicação a tìtulo de medicamentos, composições farmacêuticas e utilização

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2162 DE 12/06/2012.